These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20735311)

  • 1. Simultaneous targeting of estrogen receptor and HER2 in breast cancer.
    Azim HA; Piccart MJ
    Expert Rev Anticancer Ther; 2010 Aug; 10(8):1255-63. PubMed ID: 20735311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
    J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
    Prat A; Baselga J
    Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing the efficacy of hormonal agents with selected targeted agents.
    Johnston SR
    Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers.
    Nahta R; O'Regan RM
    Breast Cancer Res Treat; 2012 Aug; 135(1):39-48. PubMed ID: 22527112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
    Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
    J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
    Massarweh S; Schiff R
    Clin Cancer Res; 2007 Apr; 13(7):1950-4. PubMed ID: 17404074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
    Glück S; Arteaga CL; Osborne CK
    Clin Cancer Res; 2011 Sep; 17(17):5559-61. PubMed ID: 21764887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
    Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapeutic approaches in breast cancer.
    Davies E; Hiscox S
    Maturitas; 2011 Feb; 68(2):121-8. PubMed ID: 21144683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New approaches to reverse resistance to hormonal therapy in human breast cancer.
    Weinberg OK; Marquez-Garban DC; Pietras RJ
    Drug Resist Updat; 2005 Aug; 8(4):219-33. PubMed ID: 16054421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
    Bianchini G; Iwamoto T; Qi Y; Coutant C; Shiang CY; Wang B; Santarpia L; Valero V; Hortobagyi GN; Symmans WF; Gianni L; Pusztai L
    Cancer Res; 2010 Nov; 70(21):8852-62. PubMed ID: 20959472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
    Massarweh S; Schiff R
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-expressed type of ER and HER2 protein as a predictive factor in determining resistance to antiestrogen therapy in patients with ER-positive and HER2-positive breast cancer.
    Horiguchi J; Koibuchi Y; Iijima K; Yoshida T; Takata D; Rokutanda N; Nagaoka R; Oyama T; Iino Y; Morishita Y
    Oncol Rep; 2005 Nov; 14(5):1109-16. PubMed ID: 16211272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
    Colomer R; Llombart-Cussac A; Lloveras B; Ramos M; Mayordomo JI; Fernández R; Tusquets I; Gil M; Barnadas A; Constenla M; Gilabert M; Alba E
    Cancer; 2007 Nov; 110(10):2178-85. PubMed ID: 17926331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NFkappaB pathway and endocrine-resistant breast cancer.
    Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.